In:
Clinical and Molecular Hepatology, The Korean Association for the Study of the Liver, Vol. 27, No. 4 ( 2021-10-01), p. 589-602
Abstract:
Background/Aims: This study aimed to investigate whether everolimus (EVR) affects long-term survival after liver transplantation (LT) in patients with hepatocellular carcinoma (HCC).Methods: The data from 303 consecutive patients with HCC who had undergone LT from January 2012 to July 2018 were retrospectively reviewed. The patients were divided into two groups: 1) patients treated with EVR in combination with calcineurin inhibitors (CNIs) (EVR group; n=114) and 2) patients treated with CNI-based therapy without EVR (non-EVR group; n=189). Time to recurrence (TTR) and overall survival (OS) after propensity score (PS) matching were compared between the groups, and prognostic factors for TTR and OS were evaluated.Results: The EVR group exhibited more aggressive tumor biology than the non-EVR group, such as a higher number of tumors (P=0.003), a higher prevalence of microscopic vascular invasion (P=0.017) and exceeding Milan criteria (P=0.029). Compared with the PS-matched non-EVR group, the PS-matched EVR group had significantly better TTR (P 〈 0.001) and OS (P 〈 0.001). In multivariable analysis, EVR was identified as an independent prognostic factor for TTR (hazard ratio [HR], 0.248; P=0.001) and OS (HR, 0.145; P 〈 0.001).Conclusions: Combined with CNIs, EVR has the potential to prolong long-term survival in patients undergoing LT for HCC. These findings warrant further investigation in a well-designed prospective study.
Type of Medium:
Online Resource
ISSN:
2287-2728
,
2287-285X
DOI:
10.3350/cmh.2021.0038
Language:
English
Publisher:
The Korean Association for the Study of the Liver
Publication Date:
2021
detail.hit.zdb_id:
2672560-5
detail.hit.zdb_id:
2672531-9
